Drug Development and Clinical Trials

Drug Discovery & Pre-Clinical - Lab Bench Beginnings

• Goal: Identify & test potential drug candidates before human trials.
• Discovery Phases:
  • Target Identification: Pinpoint biological target (e.g., enzyme, receptor).
  • Hit Finding: Screen vast compound libraries (High Throughput Screening - HTS).
  • Lead Optimization: Refine 'hit' compounds for better efficacy, safety, ADME (📌 Absorption, Distribution, Metabolism, Excretion). Structure-Activity Relationships (SAR) studied.
• Pre-clinical Evaluation:
  • In vitro studies: Test on cells, tissues.
  • In vivo studies: Animal models.
    • Pharmacokinetics (PK) & Pharmacodynamics (PD).
    • Toxicology: Acute, sub-chronic, chronic. Determines LD₅₀, ED₅₀.
    • Therapeutic Index: $TI = LD_{50}/ED_{50}$.

  ⭐ Pre-clinical studies require testing in at least two animal species (one rodent, one non-rodent) before human trials.

• Outcome: Data compiled for Investigational New Drug (IND) application.

Clinical Trial Phases - People Power Phases

• Systematic human testing of new drugs/interventions.
• Phase 0 (Exploratory IND):
  • ~10-15 (healthy volunteers); preliminary PK/PD, microdosing. Often optional.
• Phase 1 (Safety & Dosage): 📌 Safety Screening
  • ~20-80 healthy volunteers (or specific patients); assess safety, MTD, PK/PD.
• Phase 2 (Efficacy & Dose Finding): 📌 Early Efficacy
  • ~100-300 patients with disease; evaluate efficacy (proof-of-concept), optimal dose, safety.
• Phase 3 (Confirmatory Trials): 📌 Confirm & Compare
  • ~1000-3000+ diverse patients; confirm efficacy vs. standard/placebo; monitor AEs. Pivotal RCTs for approval.

  ⭐ Phase 3 trials: typically randomized, double-blind, controlled multicenter studies for definitive efficacy/safety evidence.

• Phase 4 (Post-Marketing Surveillance): 📌 Population Perspective
  • Thousands of patients (real-world); monitor long-term safety (pharmacovigilance), rare AEs, new uses. ​

Ethics & Regulatory Aspects - Rulebook & Rights

• Guiding Frameworks:
  • Declaration of Helsinki: Global ethical principles.
  • ICH-GCP: International quality standard for trials.
  • ICMR Guidelines: India's national ethical code.
• Indian Regulatory & Oversight:
  • CDSCO: Central drug authority; trial permission.
  • IEC/IRB: Independent ethics review; min. 5 members.
  • CTRI: Mandatory clinical trial registration.
  • Key Legislation: Drugs & Cosmetics Act; New Drugs & Clinical Trials Rules, 2019.
• Informed Consent Essentials:
  • Voluntary, prior, informed, documented.
  • Includes: Purpose, procedures, risks/benefits, confidentiality, right to withdraw.
• Participant Protections: Right to safety, privacy, compensation for trial-related injury.

⭐ The New Drugs and Clinical Trials Rules, 2019, mandate specific timelines for approvals and compensation for trial-related injuries, enhancing participant protection.

Pharmacovigilance - After Approval Alerts

• Goal: Continuously monitor drug safety & efficacy in real-world settings post-marketing. Detect rare or long-term Adverse Drug Reactions (ADRs).
• Key Activities:
  • Spontaneous Reporting Systems (SRS): e.g., Pharmacovigilance Programme of India (PvPI), MedWatch (USA).
  • Signal detection: Identifying new potential causal links or new aspects of known ADRs.
  • Periodic Safety Update Reports (PSURs).
  • Risk Management Plans (RMPs).
• Regulatory Actions:
  • Label updates (e.g., Boxed Warnings).
  • Usage restrictions.
  • Drug recall or market withdrawal.
• Causality Assessment: Tools like Naranjo Algorithm, WHO-UMC criteria.

  ⭐ De-challenge (ADR subsides on drug withdrawal) and re-challenge (ADR reappears on re-exposure) are vital for assessing causality of an ADR.

High‑Yield Points - ⚡ Biggest Takeaways

• Clinical Trial Phases: Phase I (safety, healthy volunteers), Phase II (efficacy, small patient groups), Phase III (large RCTs), Phase IV (post-marketing surveillance).
• IND application precedes human trials; NDA for marketing approval.
• RCTs are gold standard for Phase III efficacy and safety assessment.
• Informed Consent is mandatory for all trial participants.
• Pharmacovigilance (Phase IV) monitors ADRs and long-term effects.
• Schedule Y (India) governs clinical trial requirements.